UR-AID N — Professional Drug Commentary
1. Disclaimer
This commentary is intended for general educational and reference purposes only and is not a substitute for the current official product information, diagnosis, or individualized advice from a qualified physician or pharmacist. Medication decisions should take into account the patient's clinical condition, renal and hepatic function, concomitant medicines, and the locally approved prescribing information.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
2. Summary
UR-AID N is an oral effervescent granule preparation containing piperazine citrate 171 mg and colchicine 0.5 mg per 5 g sachet. The current manufacturer-listed product is indicated for acute gout, short-term prophylaxis during initiation of therapy with allopurinol or uricosuric drugs, prophylaxis against urinary urate stones, and gouty arthritis. It is manufactured and licensed by Pharaonia Pharmaceuticals (Pharo Pharma), Egypt. (Pharaonia Pharma)
Colchicine provides anti-inflammatory activity in gout, while piperazine is described in the approved insert as an ingredient used in gout therapy and claimed to dissolve uric acid, producing soluble urate. Piperazine should not, however, be presented as equivalent to modern evidence-based long-term urate-lowering therapy such as allopurinol.
3. Brand Name
UR-AID N
The current manufacturer's product page identifies the product specifically as UR-AID N. (Pharaonia Pharma)
4. Category
Therapeutic category: Antigout / Urological preparation.
UR-AID N is a combination product intended for gout-related inflammatory disease and urinary urate-related conditions. It is not an antimicrobial medicine and therefore does not have an antibacterial, antiviral, antifungal, or antiparasitic therapeutic spectrum. (Pharaonia Pharma)
5. Active Ingredient
Each 5 g sachet contains:
- Piperazine citrate — 171 mg
- Colchicine — 0.5 mg
The approved insert lists the inactive ingredients as sodium bicarbonate, lactose monohydrate, citric acid anhydrous, tartaric acid, and saccharin sodium.
6. Pharmaceutical Form & Strength
Dosage form: Effervescent granules in sachets.
Strength: Each 5 g sachet contains piperazine citrate 171 mg + colchicine 0.5 mg. The current manufacturer product page lists the dosage form as sachets. (Pharaonia Pharma)
A current Egyptian pharmacy listing also identifies the commercial presentation as UR-AID N effervescent granules, 12 sachets. (Abdin Pharmacies)
7. Manufacturer & Marketing Authorization Holder
Manufacturer and License Holder:
Pharaonia Pharmaceuticals (Pharo Pharma)
New Borg El Arab, Alexandria, Egypt.
The current approved insert explicitly identifies Pharaonia Pharmaceuticals (Pharo Pharma) as the Manufacturer and License Holder. The available documentation does not separately label another entity as a distinct Marketing Authorization Holder, so no additional MAH entity is stated here without independent evidence.
8. Mechanism of Action
Colchicine
Colchicine suppresses the inflammatory response associated with monosodium urate crystal deposition. Its established pharmacological action involves interference with microtubule-dependent cellular processes, thereby reducing neutrophil migration and activation and other inflammatory responses involved in gout flares.
The approved UR-AID N insert describes colchicine as reducing the inflammatory response to deposited urate crystals and notes that it is not an analgesic in the conventional sense and is not a uricosuric agent. It is therefore used to control the inflammatory manifestations of gout rather than to correct hyperuricemia itself.
Piperazine
The approved UR-AID N insert describes piperazine as a long-established ingredient in gout treatment and states that it is claimed to dissolve uric acid, producing soluble urate. This should be understood as the pharmacological rationale presented in the product literature and should not be interpreted as evidence that piperazine replaces modern guideline-directed urate-lowering therapy.
9. Spectrum of Activity
Not applicable in the antimicrobial sense.
UR-AID N does not possess an antibacterial, antiviral, antifungal, or antiparasitic spectrum. Its pharmacological effects relate to control of gout-associated inflammation and the product's intended management of uric-acid/urate-related urinary conditions. (Pharaonia Pharma)
10. Pharmacokinetics
The current approved insert does not provide a complete modern pharmacokinetic profile for the fixed-dose UR-AID N combination as a whole.
For colchicine, the insert states that it is readily absorbed after oral administration, with peak plasma concentrations occurring after approximately 2 hours. It reports a plasma half-life of approximately 1 hour, while a substantially longer persistence of approximately 60 hours is described in leukocytes. The insert also notes enterohepatic circulation.
The insert reports that colchicine is deacetylated in the liver and is mainly excreted in the feces, with approximately 10–20% excreted in the urine; the proportion excreted in urine increases in patients with hepatic disease.
For the complete piperazine/colchicine combination, product-specific pharmacokinetic parameters are not comprehensively provided in the current approved insert. Therefore, precise combination-specific plasma concentrations, half-lives, or clearance values should not be inferred beyond the documented component information.
The insert specifically states that pharmacokinetic data are not available in children.
11. Indications
According to the current manufacturer information and approved insert, UR-AID N is indicated for:
- Management of urolithiasis
- Acute gout
- Short-term prophylaxis of gout attacks during initiation of therapy with allopurinol or uricosuric drugs
- Prophylaxis against urinary urate stones
- Gouty arthritis (Pharaonia Pharma)
The use of colchicine for acute gout is consistent with contemporary gout guidance, which recognizes colchicine as one of the first-line anti-inflammatory options for gout flares. (American College of Rheumatology)
For long-term control of hyperuricemia, UR-AID N should not be portrayed as a substitute for established urate-lowering therapy. Current ACR guidance recommends allopurinol as the preferred first-line urate-lowering therapy for most patients who require ULT, with dose titration guided by serum urate targets; anti-inflammatory prophylaxis such as colchicine is recommended during initiation of ULT. (American College of Rheumatology)
12. Administration
UR-AID N is administered orally after reconstitution in water.
The current approved insert specifies:
- For prophylaxis of gout attacks during initial treatment with allopurinol or uricosuric drugs: 1 sachet 2–3 times daily.
- For acute gout: 2 sachets initially, followed by 1 sachet every 4 hours daily, according to the approved insert.
- The insert states that doses should be reduced in patients with less severe impairment and in those with body weight below 50 kg.
Because colchicine has a narrow therapeutic window, the prescribed dose should not be exceeded. Contemporary colchicine labeling likewise emphasizes the potential for serious toxicity following excessive exposure or clinically important drug interactions.
13. Method of Preparation
Empty the contents of the sachet into water and allow the effervescent granules to dissolve before oral administration.
The preparation should be taken as a reconstituted oral solution/suspension as directed by the product information, rather than swallowed dry.
The exact volume of water and timing in relation to meals should follow the current package insert or the prescribing physician's instructions rather than relying on older secondary descriptions.
14. Contraindications
The current approved UR-AID N insert lists the following contraindications:
- Hypersensitivity to any of the ingredients
- Severe gastrointestinal disorders
- Severe renal disorders
- Severe hepatic disorders
- Severe cardiac disorders
- Blood dyscrasias
- Pregnancy
- Lactation
Importantly, contraindications associated specifically with atropine, such as narrow-angle glaucoma, myasthenia gravis, paralytic ileus, pyloric stenosis, and prostatic enlargement, should not be presented as contraindications of the current UR-AID N formulation because atropine is not included in its current approved composition.
15. Warnings & Precautions
UR-AID N requires careful use because colchicine has a narrow therapeutic window and piperazine may present additional concerns in patients with impaired renal function or neurological disease.
Colchicine
Toxicity may involve the gastrointestinal tract, bone marrow, liver, kidneys, and neuromuscular system. Severe toxicity can include bone-marrow suppression, thrombocytopenia, agranulocytosis, aplastic anemia, pancytopenia, peripheral neuropathy, myopathy, rhabdomyolysis, and multiorgan complications.
Renal impairment
Particular caution is required in renal impairment. The UR-AID N insert specifically warns about piperazine in patients with renal failure and states that care is required when renal function is impaired. Reduced renal clearance can also increase colchicine exposure and toxicity risk.
Hepatic disease
The insert advises caution in patients with hepatobiliary disorders. Hepatic dysfunction can also alter colchicine handling.
Elderly and debilitated patients
The product insert advises that colchicine should be used with great care in old and debilitated patients, who may be particularly susceptible to toxicity.
Neurological disorders
Piperazine should be used cautiously in patients with epilepsy, latent neurological disturbance, or impaired renal function, according to the approved insert.
Cardiac and gastrointestinal disease
The insert advises caution in patients with cardiac, hepatic, renal, or gastrointestinal disease.
Sodium content
The product contains sodium; this should be considered in patients following a restricted-sodium diet.
16. Drug Interactions
Important interactions documented in the current approved insert include:
- Cyclosporine: Colchicine may interact with cyclosporine, increasing colchicine exposure and the risk of toxicity, including nephrotoxicity.
- Clarithromycin: Concomitant use may produce colchicine toxicity because of increased colchicine exposure.
- Erythromycin: Concomitant use may also increase the risk of colchicine toxicity.
- The insert additionally states that colchicine may interfere with absorption of certain nutrients and may increase sensitivity to CNS depressants and enhance responses to sympathomimetic agents.
Modern colchicine pharmacology also recognizes colchicine as a CYP3A4 and P-glycoprotein substrate, making clinically important interactions with inhibitors of these pathways particularly relevant. (American College of Rheumatology)
Patients should therefore inform their physician or pharmacist about all prescription medicines, over-the-counter medicines, supplements, and herbal products before using UR-AID N.
17. Side Effects
Colchicine
The most frequent adverse effects are gastrointestinal and may include:
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
The approved insert states that these effects are related to colchicine's antimitotic activity and are often among the earliest manifestations of toxicity.
More serious colchicine toxicity may include:
- Gastrointestinal hemorrhage
- Bone-marrow depression
- Agranulocytosis
- Thrombocytopenia
- Aplastic anemia
- Pancytopenia
- Renal or hepatic damage
- Peripheral neuropathy
- Myopathy
- Rhabdomyolysis
- Rash
- Disseminated intravascular coagulation
- Alopecia
- Severe or fatal systemic toxicity in overdose
Piperazine
The approved insert describes piperazine-associated adverse effects as including:
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Headache
- Rash
- Urticaria
Rare serious neurological manifestations may include somnolence, dizziness, nystagmus, muscular incoordination, tremor, convulsions, choreiform movements, loss of reflexes, and other neurological abnormalities, particularly in association with overdose or impaired elimination.
Persistent vomiting or diarrhea, marked weakness, neurological symptoms, muscle weakness or pain, abnormal bleeding, or other signs suggestive of toxicity require prompt medical assessment.
18. Use in Special Populations
Pregnancy
Pregnancy is listed as a contraindication in the current approved UR-AID N insert.
Breastfeeding
Lactation is also listed as a contraindication in the approved insert.
Renal impairment
UR-AID N requires particular caution in renal impairment. The insert specifically warns about piperazine in renal failure and advises appropriate care in patients with impaired renal function. Colchicine exposure may also increase when renal clearance is reduced.
Hepatic impairment
Caution is required in hepatic disease because the insert identifies hepatobiliary disease as a precaution and describes hepatic involvement in colchicine disposition.
Older or debilitated patients
Use requires particular caution because these patients may be more susceptible to colchicine toxicity.
Children
The current approved insert states that pharmacokinetic data are not available in children. Product-specific safety and efficacy information for pediatric gout is insufficient to support extrapolation from adult dosing; pediatric use should therefore not be assumed to be established.
19. Storage Conditions
According to the current approved insert:
- Store at a temperature not exceeding 30°C.
- Store in a dry place.
- Keep out of reach of children.
Because this is an effervescent preparation, protecting the sachets from excess moisture is particularly important.
20. Additional Sections
Current Formulation and Regulatory Status
The current documented product is UR-AID N, containing:
Piperazine citrate 171 mg + Colchicine 0.5 mg per 5 g sachet, with no atropine listed in the current approved composition. The manufacturer currently lists UR-AID N on its website with these two active ingredients and the indications described above. (Pharaonia Pharma)
The current approved insert is dated 15 January 2025 and confirms the same composition.
Earlier UR-AID Formulation
An older UR-AID formulation contained:
- Piperazine hydrate — 0.128 g/5 g
- Colchicine — 0.3 mg/5 g
- Atropine sulfate — 0.128 mg/5 g
The Egyptian Drug Authority's technical committee decision specified for preparations containing Piperazine + Colchicine + Atropine that atropine should be removed, colchicine increased from 0.3 mg/5 g to 0.5 mg/5 g, piperazine retained, and the reformulated products identified by adding the letter N to the name. (Egyptian Drug Authority)
This explains why older Egyptian drug databases can still display Atropine sulfate + Colchicine + Piperazine. For example, one legacy database currently displays that composition but explicitly records its price update as 27 July 2024, making it an older data record rather than evidence of the current UR-AID N formulation. (DwaPrices)
Current Egyptian pharmacy listings, in contrast, identify UR-AID N EFF 12 SACHETS as the marketed presentation. (Abdin Pharmacies)
Overdose
Colchicine has a narrow therapeutic window, and overdose can be extremely serious or fatal. The approved insert states that early gastrointestinal symptoms may be delayed, with severe systemic complications developing later. Reported complications include multiorgan dysfunction, acute renal failure, neurological complications, myocardial depression, arrhythmias, respiratory failure, and cardiovascular collapse.
Because toxicity may be delayed, a suspected overdose requires urgent medical assessment even when the patient initially appears well.
Relationship to Contemporary Gout Therapy
UR-AID N should be used according to its approved indications and prescribed dosing. It should not be represented as a substitute for contemporary long-term urate-lowering management.
Current ACR guidance recommends allopurinol as the preferred first-line urate-lowering therapy for patients requiring ULT and recommends concomitant anti-inflammatory prophylaxis, such as colchicine, when ULT is initiated. For gout flares, colchicine, NSAIDs, and glucocorticoids are recognized first-line anti-inflammatory options, with treatment selected according to patient-specific factors. (American College of Rheumatology)
21. Frequently Asked Questions (FAQ)
What is UR-AID N used for?
It is indicated for acute gout, management of urolithiasis, short-term prophylaxis during initiation of allopurinol or uricosuric therapy, prophylaxis against urinary urate stones, and gouty arthritis. (Pharaonia Pharma)
What are the active ingredients in UR-AID N?
Each 5 g sachet contains piperazine citrate 171 mg and colchicine 0.5 mg. (Pharaonia Pharma)
Does the current UR-AID N formulation contain atropine?
No. The current approved formulation lists piperazine citrate and colchicine only. Egyptian regulatory documentation required removal of atropine from the older piperazine/colchicine/atropine combination and addition of N to the reformulated product name. (Egyptian Drug Authority)
Why do some websites still list atropine?
Some databases retain older product records. One such listing identifies the old atropine-containing formulation and records a price update dated July 2024, whereas the manufacturer currently lists UR-AID N with the reformulated composition. (DwaPrices)
Is colchicine a conventional painkiller?
No. Colchicine is an anti-inflammatory medicine used to suppress the inflammatory response responsible for gout-flare symptoms. The approved insert specifically states that it is not an analgesic in the conventional sense.
Is UR-AID N the same as long-term uric-acid-lowering therapy?
No. It should not be presented as equivalent to modern long-term urate-lowering therapy. When long-term urate lowering is indicated, current ACR guidance identifies allopurinol as the preferred first-line ULT for most patients, with treatment titrated to serum urate targets. (American College of Rheumatology)
Can UR-AID N be taken with clarithromycin?
Clarithromycin can substantially increase colchicine exposure and may cause serious colchicine toxicity. Concomitant use requires medical assessment and should not be undertaken without appropriate professional guidance.
Is UR-AID N suitable during pregnancy or breastfeeding?
The current approved insert lists both pregnancy and lactation as contraindications.
What should be done after an overdose?
A suspected overdose should be treated as a medical emergency, because serious colchicine toxicity can be delayed and may become life-threatening even when early symptoms are mild or absent.
Can children use UR-AID N?
The approved insert states that pharmacokinetic data are not available in children, and there is insufficient product-specific evidence to assume established pediatric dosing. Pediatric use should therefore be determined by a qualified physician rather than extrapolated from adult dosing.
22. References
- Pharaonia Pharmaceuticals (Pharo Pharma). UR-AID N – Current Manufacturer Product Page. Current active ingredients, indications, and dosage form. (Pharaonia Pharma)
- Pharaonia Pharmaceuticals / Central Administration for Pharmaceutical Care. UR-AID N Effervescent Granules — Approved Insert, Approval Date 15 January 2025. Composition, properties, indications, dosage, contraindications, adverse reactions, interactions, precautions, overdose, pharmacokinetics, packaging, storage, and manufacturer/license-holder information.
- Egyptian Drug Authority (EDA). Technical Committee Decisions. Decision concerning effervescent preparations containing Piperazine + Colchicine + Atropine, requiring removal of atropine, increasing colchicine from 0.3 mg/5 g to 0.5 mg/5 g, retention of piperazine, and addition of N to the reformulated product name. (Egyptian Drug Authority)
- FitzGerald JD, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research. Guidance on acute gout treatment, colchicine, anti-inflammatory prophylaxis during ULT initiation, and long-term urate-lowering therapy. (American College of Rheumatology)
- DwaPrices. Ur-Aid eff. granul. 12 sachets. Legacy Egyptian product listing showing the older atropine-containing composition and a price-update date of 27 July 2024; useful for distinguishing historical records from the current UR-AID N formulation. (DwaPrices)
- Current Egyptian pharmacy listings. Listings identifying UR-AID N EFF 12 SACHETS as a current commercial presentation in Egypt. (Abdin Pharmacies)
Final Scientific Status
The current evidence supports describing the presently documented product as UR-AID N, with piperazine citrate 171 mg + colchicine 0.5 mg per 5 g sachet and no atropine. The older atropine-containing UR-AID formulation is a historical formulation that remains visible in some older Egyptian databases. The Egyptian Drug Authority documentation provides the regulatory bridge between the two formulations, while the manufacturer's current product page and its approved insert dated 15 January 2025 confirm the current UR-AID N composition. (Egyptian Drug Authority)
This distinction is important because atropine-specific contraindications and precautions should not be attributed to the current UR-AID N formulation solely on the basis of the obsolete composition.